Clin Lab. 2023 Nov 1;69(11). doi: 10.7754/Clin.Lab.2023.230210.
The goal was to detect the levels of immunoglobulin (Ig) and complements (C) in patients newly diagnosed as multiple myeloma (MM) and to analyze their value in evaluating the efficacy of bortezomib and the impact on survival time.
A total of 125 patients newly diagnosed as MM admitted to our hospital were included into the research group, while another 118 healthy volunteers were recruited into the control group. The effectiveness of Ig and C in efficacy evaluation after treatment with bortezomib and the influencing factors for the survival rate were analyzed. Moreover, survival analysis was conducted.
The response rate was 78.51% in the research group. The sensitivity and area under the curve (AUC) of combination of serum IgG, κ light chain, λ light chain, C3 and C4 levels in efficacy evaluation were 97.89% and 0.791, respectively, which were superior to those of any single indicator (p < 0.05). The proportion of stage III cases and the levels of serum IgG, κ light chain, λ light chain, C3 and C4 among the dead patients were higher than those among the surviving patients (p < 0.05). Stage III, serum IgG, κ light chain, λ light chain, C3 and C4 were all the risk factors for death in the research group. The increase in the above indicators was associated with the death of patients (p < 0.05).
The combination of serum IgG, κ light chain, λ light chain, C3 and C4 levels can be more effective than any single indicator in efficacy evaluation of bortezomib.
目的在于检测新诊断为多发性骨髓瘤（MM）患者的免疫球蛋白（Ig）和补体（C）水平，并分析其在评估硼替佐米疗效和对生存时间影响中的价值。
选取我院收治的 125 例新诊断为 MM 的患者作为研究组，另选取同期 118 例健康志愿者作为对照组。分析 Ig 和 C 在硼替佐米治疗后的疗效评估中的作用及影响患者生存率的因素，并进行生存分析。
研究组的有效率为 78.51%。血清 IgG、κ 轻链、λ 轻链、C3 和 C4 联合检测在疗效评估中的灵敏度和曲线下面积（AUC）分别为 97.89%和 0.791，均优于单一指标（p<0.05）。死亡患者的Ⅲ期病例比例及血清 IgG、κ 轻链、λ 轻链、C3 和 C4 水平均高于存活患者（p<0.05）。Ⅲ期、血清 IgG、κ 轻链、λ 轻链、C3 和 C4 均是研究组死亡的危险因素。上述指标升高与患者死亡相关（p<0.05）。
血清 IgG、κ 轻链、λ 轻链、C3 和 C4 水平联合检测比任何单一指标在硼替佐米疗效评估中更有效。
